<DOC>
	<DOCNO>NCT03038295</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy oral/local propranolol preterm newborn diagnose early phase retinopathy prematurity ( ROP ) .</brief_summary>
	<brief_title>Prospective Cohort Study Propranolol Treatment Retinopathy Prematurity</brief_title>
	<detailed_description>The incidence Retinopathy Prematurity ( ROP ) preterm newborns less 1500g 60 % developed country around world , much preterm newborns 1500g 32 week gestational age Retinopathy Prematurity ( ROP ) treat develop country . ROP list top five cause lead blindness child , seriously threated child 's vision quality life . The ablation retina photocoagulation laser cryotherapy reduces incidence blindness suppress neovascular phase ROP . However , Surgeries require anesthesia may result complication apnea , neonatal necrotizing enterocolitis , sepsis , hemorrhage digestive tract . As result , 's important study alternative non-surgical treatment method . The development ROP depend largely vascular endothelial growth factor ( VEGF ) . The reduction VEGF expression neovascular phase might prevent destructive neovascularization ROP . Propranolol kind beta-adrenergic receptor ( Î²-AR ) inhibit expression VEGF first choice treat infantile hemangioma , common tumor infancy . There pilot study suggest administration oral propranolol effective counteract progression ROP patient without operation indication . Nevertheless safety concern , oral propranolol may result associated complication side effect bradycardia , hypotension , injury cerebrum growth olfactory . Recently research eye drop propranolol mouse model oxygen-induced retinopathy ( OIR ) show propranolol still effective inhibit angiogenic process , indicate local administration equally effective . The purpose study evaluate safety efficacy oral/local propranolol preterm newborns early phase retinopathy prematurity ( ROP ) .The study follow period time , observe development optic nerve system complication confirm efficacy propranolol ROP treatment , provide theoretical basis futher clinical application drug ROP .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Retinopathy Prematurity</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Preterm newborn ( birth weight le 1500g ) stage 1/2 ROP Zone 2 3 without plus A sign parental inform consent Newborns heart failure Newborns recurrent bradycardia ( heart rate &lt; 90 beat per minute ) Newborns second third degree atrioventricular block Newborns congenital cardiovascular anomaly , except persistent ductus arteriosus , patent foramen ovale small ventricular septal defect Newborns hypotension Newborns renal failure Newborns actual cerebral haemorrhage Newborns diseases contraindicate use betaadrenoreceptor blocker . Newborns severe stage ROP stage 2 Zone 1</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>8 Weeks</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Retinopathy Prematurity</keyword>
	<keyword>propranolol</keyword>
	<keyword>ROP</keyword>
</DOC>